AstraZeneca Boosts Coppell Manufacturing with $445 Million Expansion

Pharmaceutical company AstraZeneca has announced a significant expansion of its manufacturing site in Coppell, Texas, investing $445 million to double the production capabilities of its drug Lokelma. This site is the exclusive manufacturer of Lokelma, which treats hyperkalemia, a medical condition caused by elevated potassium levels in the blood. The expansion is expected to create approximately 30 new skilled jobs within the company.

The ribbon-cutting ceremony held on October 15, 2025, marked the official unveiling of the expanded facility. City officials from Coppell and representatives from the Texas state government joined AstraZeneca executives to celebrate this milestone. Company spokesperson Lauren-Jei McCarthy confirmed that major construction is already finished, with two new manufacturing lines set to begin operations in 2026.

The expansion includes a new 9,000-square-foot building that houses advanced manufacturing lines and administrative space, enhancing the site’s overall operational efficiency. Currently, the Coppell facility employs around 250 people, and the additional roles will further bolster the local economy.

AstraZeneca’s investment reflects its commitment to meeting the growing demand for Lokelma, which has become essential for patients suffering from hyperkalemia. The company’s strategic move not only aims to increase production but also reinforces its presence in the Texas pharmaceutical landscape.

As the global demand for effective treatments continues to rise, AstraZeneca’s expansion positions it well to respond to the needs of healthcare providers and patients alike. This development signifies a robust investment in both the community and the future of healthcare solutions.